January 27, 2015 2:00 PM ET

Biotechnology

Company Overview of Intrexon Corporation

Company Overview

Intrexon Corporation, a biotechnology company, operates in the synthetic biology field. Synthetic biology is a discipline that applies engineering principles to biological systems. The company designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components using its proprietary and complementary technologies. Its proprietary and complementary technologies comprise UltraVector gene design and fabrication platform, which is an integrated suite of tools comprising DNA construction technology and components, cellular and protein engineering tools, computational models, and statistical methods; Cell systems informatics, a bioinformatics software and da...

222 Lakeview Avenue

Suite 1400

West Palm Beach, FL 33401

United States

Founded in 1998

223 Employees

Phone:

561-410-7000

Key Executives for Intrexon Corporation

Chairman
Age: 60
Chief Operating Officer
Age: 49
Total Annual Compensation: $2.1M
Senior Vice President of Energy & Chemicals Sector and President of Industrial Products Division
Age: 56
Total Annual Compensation: $341.0K
Compensation as of Fiscal Year 2013.

Intrexon Corporation Key Developments

Intrexon Corporation and ZIOPHARM Oncology Announce Licensing Agreement with The University of Texas MD Anderson Cancer Center

Intrexon Corporation and ZIOPHARM Oncology announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. The licensed technologies arise from the laboratory of Laurence Cooper, M.D., Ph.D., professor of pediatrics at MD Anderson and Perry Hackett, Ph.D., professor within the College of Biological Sciences at Minnesota. The Cooper and Hackett laboratories have pioneered the design and clinical investigation of novel chimeric antigen receptor (CAR) T cell therapies using non-viral gene integration platforms. MD Anderson has built on this technology to deliver patient-derived T cells, as well as innovative approaches to generating products for universal off-the-shelf applications. When combined with Intrexon’s technology suite and ZIOPHARM’s clinically tested RheoSwitch Therapeutic System® interleukin-12 modules, the resulting proprietary methods and technologies may help realize the promise of genetically modified CAR T cells by tightly controlling cell expansion and activation in the body, minimizing off-target effects and toxicity while maximizing therapeutic efficacy. Under the terms of the agreement, MD Anderson shall receive consideration of $100 million; $50 million from each Intrexon and ZIOPHARM, payable in shares of their respective common stock, as well as a commitment of $15 to $20 million annually over three years for researching and developing the technologies.

Intrexon Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 08:30 AM

Intrexon Corporation Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-14-2015 08:30 AM. Venue: Westin St. Francis Hotel, San Francisco, California, United States. Speakers: Randal J. Kirk, Chairman, Chief Executive Officer and President.

Intrexon Corporation Appoints Peter Emtage as Vice President, Synthetic Immunology

Intrexon Corporation announced the appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology. Dr. Emtage will focus on further advancing the company's oncology and immunology platforms to bring the next generation of cellular-based solutions that overcome the limitations of current treatments and address the most challenging malignancies. Dr. Emtage brings to Intrexon over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Most recently, Dr. Emtage was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune.

Similar Private Companies By Industry

Company Name Region
Taiga Biotechnologies, Inc. United States
Angiomics, Inc. United States
EMD Biosciences, Inc. United States
Actis Biologics, Inc. United States
Excelimmune, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 26, 2015
Exemplar Genetics LLC
Merger/Acquisition
July 1, 2014
Trans Ova Genetics LC
Private Placement
March 26, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Intrexon Corporation, please visit www.dna.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.